The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an ...

Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others People taking popular new ...

People taking popular new weight-loss drugs such as Wegovy and Zepbound often celebrate the number of pounds they shed and ...

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in ...

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...

This article was reviewed by Darragh O’Carroll, MD. Long-Term Side Effects of Wegovy® Key takeaways: The long-term side ...

It might sound shocking to read about such drastic actions, but it’s stories of overweight children being bullied and too ...

Somehow, it’s becoming even harder to get a GLP-1.

Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver ...

Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded ...

BMI is a measure of body weight relative to height. The goal for most people is to have a BMI that’s over 18 and under 25.

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.